

**In the Claims:**

For the Examiner's convenience, Applicants present all pending claims with status indicators in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c)(1).

Please cancel claims 1-29 and 32. Additionally, please amend claims 30, 33-35 and add new claims 36-37 as follows:

Claims 1-29 CANCEL

30. (CURRENTLY AMENDED) A method of detecting a disease-state in a subject, wherein the disease-state is associated with expression of an RG1 polypeptide having the amino acid sequence of SEQ ID NO: 2, and wherein the method comprises:
- (a) administering to the subject an immunoconjugate ~~of Claim 22~~, wherein the immunoconjugate comprises an antibody or a fragment or a variant thereof that specifically binds to an epitope present in the RG1 polypeptide having the amino acid sequence of SEQ ID NO: 2 and wherein the antibody or the fragment or the variant thereof is conjugated to a molecule which is a detectable marker;
  - (b) detecting the ~~binding of the immunoconjugate within the subject~~; and
  - (c) determining if the level of binding of the immunoconjugate ~~in the subject~~ is increased as compared with the level of binding detected in disease-free control subjects, an increased level being indicative of a disease state.
31. (PREVIOUSLY PRESENTED) The method of Claim 30, wherein the method of detection is immunoscintigraphy.

32. (CANCEL)
33. (CURRENTLY AMENDED) The method of Claim ~~32~~ 30, wherein the method of detection is positron emitting tomography.
34. (CURRENTLY AMENDED) The method of Claim ~~33~~ 30, wherein the detectable marker of the immunoconjugate is selected from a group consisting of  $^{43}\text{Sc}$ ,  $^{44}\text{Sc}$ ,  $^{52}\text{Fe}$ ,  $^{55}\text{Co}$ ,  $^{68}\text{Ga}$ ,  $^{64}\text{Cu}$ ,  $^{86}\text{Y}$ ,  ~~$^{94}\text{Tc}$~~ ,  $^{111}\text{In}$ , or  $^{90}\text{Y}$ .
35. (CURRENTLY AMENDED) The method of Claim ~~34~~ 30, wherein the disease-state is prostate cancer.
36. (NEW) The method of claim 30, wherein the detectable marker is a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme.
37. (NEW) The method of claim 30, wherein the antibody is selected from a group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody and a fully-human antibody.